Additionally, the oncogenic KRAS mutation-suppressed pancreatic tumor suppressor F-box and WD repeat domain-containing 7 (FBW7) suppressed glycolysis in pancreatic cancer cells and improved the effectiveness of gemcitabine in xenograft models [212]. The gene discussed is KRAS; the disease is pancreatic neoplasm.